Sharon Marsh

Sharon Marsh

Auto-generated profile, based on publicly available information

Sharon Marsh

Washington University School of Medicine, Division of Oncology, St Louis, MO 63110, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2007 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SMSharon Marsh
Sharon Marsh
JPJim Paul
Jim Paul
CKCristi R. King
Cristi R. King
GGGillian Gifford
Gillian Gifford
HMHoward L. McLeod
Howard L. McLeod
RBRobert Brown
Robert Brown
Purpose: Standard therapy for advanced ovarian cancer consists of a platinum agent in combination with a taxane, which has a 5-year survival rate of approximately 45%. The large individual variability for ovarian cancer patients in both outcome and toxicity risk from chemotherapy makes the identification of pharmacogenetic markers that can be used to screen patients before therapy selection an attractive prospect. Patients and Methods: We assessed 27 selected polymorphisms based on previously described associations or putative functional effects in 16 key genes from pathways that may influence cellular sensitivity to taxanes (ABCB1, ABCC1, ABCC2, ABCG2, CDKN1A, CYP1B1, CYP2C8, CYP3A4, CYP3A5, MAPT, and TP53) and platinum (ABCC2, ABCG2, ERCC1, ERCC2, GSTP1, MPO, and XRCC1) using polymerase chain reaction and Pyrosequencing in 914 ovarian cancer patients from the Scottish Randomised Trial in Ovarian Cancer phase III trial who were treated at presentation with carboplatin and taxane regimens after cytoreductive surgery. Results: No reproducible significant associations between genotype and outcome or toxicity were found for any of the genes analyzed. Previously reported genotype associations could not be replicated in this large study of a well-defined patient population within one specific clinical trial. Conclusion: There are no clear candidates for taxane/platinum pharmacogenetic markers. This study highlights the need for validation of putative genetic markers in large, well-defined clinical sample sets.

26 October 2005 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
SMSharon Marsh
Sharon Marsh

16 January 2007 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
SMS Marsh
S Marsh
GSG Somlo
G Somlo
XLX Li
X Li
PFP Frankel
P Frankel
CKC R King
C R King
TST W Synold
T W Synold

21 August 2004 in Journal of Human Genetics
Verified
Journal Article
Open access
SMSharon Marsh
Sharon Marsh
CKCristi R. King
Cristi R. King
RARanjeet Ahluwalia
Ranjeet Ahluwalia
HMHoward L. McLeod
Howard L. McLeod
Journal of Human Genetics, official journal of the Japan Society of Human Genetics, publishes original articles and reviews on all aspects of human genetics, including medical genetics and genomics

15 August 2003
Verified
Journal Article
Closed access
RMRon Mathijssen
Ron Mathijssen
SMSharon Marsh
Sharon Marsh
MKMats O. Karlsson
Mats O. Karlsson
RXRujia Xie
Rujia Xie
SBSharyn D. Baker
Sharyn D. Baker
HMHoward L McLeod
Howard L McLeod

1 October 2004 in Pharmacogenomics
Verified
Journal Article
Closed access
SMSharon Marsh
Sharon Marsh
HMHoward L McLeod
Howard L McLeod
Irinotecan is an anticancer drug approved in combination therapy for advanced colorectal cancer. Severe, life-threatening toxicities can occur from irinotecan treatment. Although multiple genes may play a role in irinotecan activity, the UDP glycuronosyltransferase 1 family, polypeptide A1 (UGT1A1) enzyme has been strongly associated with toxicity. A common dinucleotide repeat polymorphism in the UGT1A1 promoter region (UGT1A1*28) has been correlated with severe toxicity in cancer patients receiving irinotecan-containing therapy. Prospective screening of patients prior to chemotherapy selection may reduce the frequency of severe toxicities by allowing alternate therapy selections for patients carrying the UGT1A1*28 polymorphism.